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Abstract 47 
Objective: To perform a systematic review of published literature on adrenal biopsy and assess its   48 
performance in diagnosing adrenal malignancy.  49 
Methods: Medline In-Process & Other Non-Indexed Citations, MEDLINE, EMBASE, and Cochrane 50 
Central Register of Controlled Trial were searched from inception to February 2016. Reviewers 51 
extracted data and assessed methodological quality in duplicate. 52 
Results: We included 32 observational studies reporting on 2174 patients (39.4% women, mean 53 
age 59.8 years) undergoing 2190 adrenal mass biopsy procedures.  Pathology was described in 54 
1621/2190 adrenal lesions (689 metastases, 68 adrenocortical carcinomas , 64 other malignant, 464 55 
adenomas, 226 other benign, 36 pheochromocytomas, 74 other). The pooled non-diagnostic rate (30 56 
studies, 2030 adrenal biopsies) was 8.6% (CI 6.1%-11%). The pooled complication rate (25 studies, 57 
1356 biopsies) was 2.4% (CI 1.5%-3.3%). Studies were at a moderate risk for bias. Most limitations 58 
related to patient selection, assessment of outcome and adequacy of follow up. Only 8 studies (240 59 
patients) could be included in the diagnostic performance analysis with sensitivity and specificity of  60 
87% and 100% for malignancy; 70% and 98% for adrenocortical carcinoma ; and 87% and 96% for 61 
metastasis.  62 
Conclusions: Evidence based on small sample size and moderate risk of bias suggests that 63 
adrenal biopsy appears to be most useful in the diagnosis of adrenal metastasis in patients with a 64 
history of extra-adrenal malignancy. Adrenal biopsy should only be performed if the expected 65 
findings are likely to alter the management of the individual patient and after biochemical exclusion 66 
of catecholamine-producing tumors to help prevent potentially life-threatening complications.  67 
 68 
 69 
 70 
 71 
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Introduction 72 
 73 
Widespread use of imaging has resulted in an increased discovery of incidental adrenal masses 74 
described in around 5% of abdominal imaging studies1, 2     While most adrenal tumors are benign, 75 
many have indeterminate imaging characteristics as the specificities for diagnosing malignancy is 76 
suboptimal for the most commonly employed imaging modalities, computed tomography (CT)  and  77 
magnetic resonance imaging (MRI) 3, 4. Pre-test probability of an indeterminate adrenal mass being 78 
malignant is much greater in a patient with a history of extra-adrenal malignancy, in some series 79 
described as high as 50-75%5-10. Justifiably, in such circumstances, additional investigations are 80 
warranted, especially if a definitive diagnosis alters the management in the patient concerned. Other 81 
indicators of possible underlying malignancy are adrenal mass size and accelerated interval tumor 82 
growth, however their predictive value has been either insufficiently investigated or found to have low 83 
specificity11, 12. The current approach to patients with a newly discovered adrenal mass in the context 84 
of a history of extra-adrenal malignancy includes follow up interval imaging to assess tumor growth, 85 
additional imaging studies such as FDG-PET and/or referral for image-guided adrenal biopsy.  86 
 87 
Pathologists regularly struggle to differentiate a benign from a malignant adrenocortical or 88 
adrenomedullary mass even when having the entire tumor specimen available, therefore an adrenal 89 
biopsy usually does not have a role in the differential diagnosis of true adrenal incidentalomas. 90 
However, in the context of patients with a history of an extra-adrenal malignancy undergoing follow-91 
up monitoring or diagnostic work-up, an adrenal biopsy can confirm an adrenal metastasis without 92 
delay. Much more rarely, a diagnostic adrenal biopsy may avoid unnecessary surgery by identifying 93 
other underlying pathologies such as primary adrenal lymphoma, infection or hemorrhage. However, 94 
adrenal biopsy is an invasive, expensive procedure with a potential for non-diagnostic results and 95 
complications. Rates of non-diagnostic adrenal biopsy rates have been reported to vary widely8, 13-15 96 
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though it is unclear what factors influence this outcome. Adrenal biopsy complications vary in 97 
severity with both immediate and delayed onset complications previously described16-18. In addition, 98 
if clinicians fail to biochemically exclude the presence of pheochromocytoma prior to biopsy, an 99 
unplanned biopsy of a catecholamine-producing tumor can result in severe complications19, 20. 100 
 101 
The performance of adrenal biopsy in making the diagnosis of malignancy is unclear. Published 102 
studies investigating diagnostic parameters of adrenal biopsy include a small number of participants 103 
and employ a variety of adrenal biopsy techniques.  Moreover, the results of adrenal biopsy are 104 
compared to a reference standard that varies considerably between studies, thus making any 105 
confident conclusions impossible. 106 
 107 
Our objectives were: 108 
1) To systematically review published literature on adrenal biopsy with a special attention to 109 
patient populations, indications of adrenal biopsy  procedural  descriptions. 110 
2) To quantify the rate of non-diagnostic adrenal biopsies. 111 
3) To describe and quantify complications ensued from the adrenal biopsy procedure. 112 
4) To establish the performance of adrenal biopsy in the diagnosis of malignancy. 113 
 114 
Methods: 115 
This systematic review was conducted based on standard methods recommended by the Cochrane 116 
Collaboration for Systematic Reviews of Diagnostic Test Accuracy 21 and followed a predefined 117 
protocol. This report follows the standards set in the Preferred Reporting Items for Systematic 118 
Reviews and Meta-analysis (PRISMA) statement 22 and reports on the diagnostic accuracy of 119 
adrenal biopsy in malignant adrenal masses and also on the non-diagnostic rates and complication 120 
rates for the adrenal biopsy procedure. 121 
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Data sources and Searches  122 
A comprehensive search of several databases from each database’s inception to February 24th, 123 
2016, for English language articles was conducted. The databases included Medline In-Process & 124 
Other Non-Indexed Citations, MEDLINE, EMBASE, and Cochrane Central Register of Controlled 125 
Trials.  The search strategy was designed and conducted by an experienced librarian with input from 126 
the study’s principle investigator (IB). Controlled vocabulary supplemented with keywords were used 127 
to search for original research of adrenal biopsy, percutaneous fine needle aspiration of adrenal 128 
mass, or core adrenal biopsy.  The full search strategy is available in Supplemental Table 1. The 129 
reference lists from primary studies and narrative reviews were searched and we included any 130 
manually identified additional references that might have been missed by our initial search strategy.  131 
Reviewers working independently and in duplicate reviewed all abstracts and selected full-text 132 
manuscripts for eligibility. Disagreements at full text screening were resolved by consensus. 133 
Study Selection 134 
We searched for randomized clinical trials, observational studies and case series describing 135 
experience with adrenal biopsy procedure in patients with adrenal tumors and reporting one or more 136 
of the following outcomes: (i) complication rate of adrenal biopsy procedure, (ii) non-diagnostic rate 137 
of adrenal biopsy procedure (failure to obtain sufficient tissue material to make histological 138 
diagnosis), and/or (iii) diagnostic performance of adrenal biopsy. We included only studies in English 139 
that reported data on more than 10 patients undergoing any kind of adrenal biopsy procedure. Case 140 
reports and case-control studies were excluded. Adrenal biopsy was defined as non-diagnostic when 141 
the amount of tissue material generated from the adrenal biopsy that was insufficient to obtain a 142 
histopathological or cytological diagnosis. We accepted any definition of complications reported by 143 
the authors. 144 
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For the diagnostic accuracy analysis of adrenal biopsy, we included only studies fulfilling the 145 
following criteria: 146 
(i) Reference standard  147 
a. includes either 1) histology following adrenalectomy or autopsy, 2) imaging follow up 148 
after  3-12 months, or 3) or clinical follow up for at least 2 years.  149 
b. is reported for at least 50% of patients with malignant adrenal masses (disease positives) 150 
and at least 50% of patients with benign adrenal masses (disease negatives) undergoing 151 
adrenal biopsy 152 
(ii) Studied population included fewer than 30% patients in whom the adrenal lesion could not 153 
be conclusively classified as either benign or malignant.  154 
 155 
Data extraction  156 
Data extraction was carried out independently and in duplicates by independent pairs of reviewers 157 
(IB, DD, ST, MS, FA) using DistillerSR software from Evidence Partners 23 to collect information from 158 
each eligible study. For each study the following were collected: last name of first author and year of 159 
publication, the country where the study was conducted, study objective, type of study, study 160 
population, time interval of patient enrolment, inclusion and exclusion criteria, patient age and 161 
gender, number of patients who underwent biopsy, number of adrenal biopsies (CT guided, US 162 
guided, endoscopic US guided, others), needle gauge, number of needle passes, non-diagnostic 163 
biopsies, adrenal mass characteristics related to malignant and benign categories and subcategories 164 
(number, tumor size, reference standard, complications) and diagnostic accuracy parameters for 165 
adrenal biopsy. Discrepancies in data extraction were resolved by consensus or by a third reviewer. 166 
 167 
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Quality assessment  168 
Authors working independently and in duplicates analyzed the full text of articles eligible for 169 
diagnostic accuracy to assess the reported quality of the methods. For the studies selected for 170 
diagnostic accuracy analysis, we assessed the risk of bias and the applicability of findings related to 171 
patient selection, index test, reference standard using QUADAS-2, the current best tool for quality 172 
assessment of studies of diagnostic accuracy in systematic reviews, tailored to the review topic. 173 
Patient flow, timing and exclusion, a part of QUADAS-2, was not assessed as it was not relevant to 174 
our topic.  175 
Patient selection was regarded at high risk of bias if either consecutive or random selection was not 176 
used, or patients were selected from an adrenalectomy database, or case control design was used, 177 
or patients were inappropriately excluded based on tumor size or specific imaging characteristics or 178 
difficult to diagnose patients. Index Test (adrenal biopsy) interpretation was considered at high risk of 179 
bias when it was reviewed knowing the results of the reference standard. Reference standard 180 
implementation was considered at high risk of bias if the final diagnosis of malignancy was reached 181 
without histopathology or if any benign diagnosis was reached by imaging follow up of less than 6 182 
months (in patients without histopathology).  183 
High concern about applicability was noted for studies where adrenal biopsy procedure and 184 
interpretation was not described in sufficient detail to allow replication or if some patients could not 185 
be disaggregated (more than 10% pheochromocytomas or neuroblastomas, etc) in the disease 186 
negative group, and/or up to 10% of ‘benign’ tumors (cysts, myelolipomas, etc) were included as 187 
disease positive.  188 
For observational studies reporting complications, quality was assessed for several parameters: 189 
representativeness of patient sample, ascertainment of complication, and the length and adequacy 190 
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of follow up were noted for each study. An overall judgment for each of these elements of low, 191 
moderate, or high risk of bias was made. 192 
Data Synthesis and Statistical Analysis 193 
We investigated the relation of complications and non-diagnostic adrenal biopsies to the experience 194 
at the institute (the number of biopsies per year as a surrogate marker) by liner regression model. 195 
Heterogeneity between studies was assessed using the I2 statistic. 196 
Meta-analysis was conducted by fitting a two-level mixed logistic regression model, with independent 197 
binomial distributions for the true positives and true negatives within each study, and a bivariate 198 
normal model for the logit transforms of sensitivity and specificity between studies. The analysis was 199 
done using STATA, version 14 (StataCorp, College Station, TX). We estimated sensitivity, 200 
specificity, positive and negative likelihood ratios, and diagnostic odds ratios (DORs), with 95% 201 
confidence intervals (CIs).  202 
Results 203 
Included Studies  204 
A total of 173 references were identified with the initial database screening. Reference list screening 205 
of the primary studies yielded  two  more references.  Of the 175 studies, 95 were excluded based 206 
on abstract screening and 80 full text papers were reviewed. Of these, 32 studies 7-10, 13, 16, 17, 21, 22, 24-207 
43
 reported at least one outcome of interest and were included. Studies were primarily excluded due 208 
to no outcome of interest (n=19), <10 patients (n=12), abstract only without subsequent full paper 209 
publication (n=8), patient overlap (n=7), ex-vivo biopsy (n=1) and case-control study (n=1). Only 8 210 
studies8, 13, 32, 33, 36-38, 43 were included for the diagnostic accuracy analysis, reasons for exclusion 211 
being lack of any or optimal reference standard for at least 50% patients (n=20) or more than 30% 212 
patients with adrenal lesions that could not be classified as either benign or malignant in benign 213 
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cohort (n=4), Supplemental Figure 1. The chance-adjusted inter-reviewer agreement was 214 
calculated using the statistic for abstract (kappa = 0.64) and for full-text screening (kappa=0.97).  215 
The summary characteristics of the included studies are presented in Table 1. A total of 2174 216 
patients (13-188 per study) were reported to undergo adrenal biopsy. Patients’ age ranged between 217 
1.2 to 88 years16, 31, though mainly included older patients (mean 59.8 years), women representing 218 
39.4% (722/1832 patients of the 29 studies that reported sex). The study population included mainly 219 
patients with established or suspected extra-adrenal malignancy (15 studies, 1110 patients), 220 
selected populations with either indeterminate masses, specific size thresholds and patients 221 
undergoing adrenalectomy (5 studies, 198 patients) and all comers (12 studies, 866 patients). 222 
However, even in “all comers” prevalence of malignant adrenal masses ranged between 18% and 223 
70%13, 25, 26, 28, 30, 32, 42, suggesting a highly selected population (Table 1). 224 
Information on a total of 2190 adrenal biopsies (13 to 277 per study) was reported in 32 studies, 225 
Table 2. Most of the biopsies were performed either in the United States (n=1390, 63%; 15 studies) 226 
or Europe (n=731, 33%; 13 studies). Mean diameter of the mass was 3.9 cm. Adrenal biopsy was 227 
performed under Computed Tomography (CT) guidance in 985 (45%) patients (17 studies), under 228 
ultrasound (US) guidance in 265 (12%) patients (11 studies), through endoscopic ultrasound in 300 229 
(13.7%) patients (5 studies), and a mixture of  CT or US guidance in 48 (2.2%) patients. In 592 230 
(27%) procedures, type of image guidance was not reported (Table 2). Needle gauge used for 231 
adrenal biopsy ranged from 16 to 25 gauge, though 22 gauge was most frequently employed. 232 
Number of needle passes ranged from 1 to 7 passes per procedure, with most studies reporting 3 to 233 
4 passes on average per procedure. 234 
The pathology of adrenal lesions (confirmed by reference standard where available) was reported 235 
only for 1621/2190, 74% cases. Out of these, 828 (51%) were classified as malignant lesions, 718 236 
(44%) as benign while the remaining 75 (5%) were not classified as either benign or malignant. 237 
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Of the 828 malignant lesions, the majority were metastases of an extra-adrenal malignancy (n=689, 238 
83%), with the rest representing  adrenocortical carcinomas (n=68, 8%), primary adrenal lymphomas 239 
(n= 17, 2%), neuroblastomas (n=7,<1% )  other malignant lesions (n=4, <1%) or not specified (n=43, 240 
5%). The specific extra-adrenal primary tumor from which the adrenal metastases originated was 241 
reported in 517 cases: lung (n=348, 67.3%), kidney (n=39, 7.6%), melanoma (n=16, 3%), 12 (2.3%) 242 
each from liver, breast and colon, 11 (2.1%) from esophagus, 6 (1.2%) from bladder and 5 (1%) from 243 
pancreas.  The remaining metastases (56, 10.8%) were from unknown primary, squamous cell 244 
carcinoma, multiple myeloma, stomach, pancreas, osteosarcoma, ovary and stomach. After 245 
excluding lung cancer only studies, in 17 studies reporting on the origin of 409 metastatic lesions, 246 
the three most common malignancies were lung (234, 57%), gastrointestinal (43, 10.5%) and kidney  247 
(42, 10%) cancers (Table 3). 248 
Of the 718 benign lesions, 464 (65%) were reported to be adrenocortical adenomas, 12 (1.7%) were 249 
myelolipomas, 7 (1%) were cysts,  5 (<1%) were ganglineuromas, 4 (<1%) were hematomas, while 250 
226 (31%) were reported as “benign”, but the underlying distinct pathology was not specified by 251 
authors (and possibly included benign adrenal lesions other than adrenocortical adenomas).  252 
The remaining 75/1621 (%) lesions that were not  classified as either benign or malignant adrenal 253 
lesions included pheochromocytomas (n=36), infection (n=29; histoplasmosis n=15, tuberculosis 254 
n=14), and other (n=10), Table 1. 255 
 The pooled non-diagnostic rate derived from 30 studies (2030 adrenal biopsy procedures) was 8.7% 256 
(CI 6.2%-11.2%; I2 = 84%, p<0.001) Figure 1. Correlation with needle gauge or number of passes 257 
used was not possible due to under-reporting and variability of techniques used. No relationship of 258 
non-diagnostic rates to the number of adrenal biopsies performed in a year (reflecting center 259 
experience) was observed (R2= 0.0175). 260 
 261 
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The pooled overall complication rate derived from 25 studies (1356 biopsies) was 2.5% (CI 1.5%-262 
3.4%; I2 = 19%, p=0.195) Figure 2. Reported practices for detection and monitoring of complications 263 
varied in the studies. Major complications (those requiring hospitalization/intervention) were adrenal 264 
hematoma (n=7), pancreatitis (n=2), pneumothorax requiring chest tube placement (n=2), 265 
hemothorax (n=1), perirenal hematoma (n=1), duodenal hematoma (n=1), hypertensive crisis (n=1) 266 
and minor complications (self-limiting/ not needing intervention or hospitalization) included 267 
pneumothorax (n=12), hematomas [perinephric (n=2), intra hepatic (n=2), subcapsular (n=1), other 268 
(n=3)], self-resolved pain (n=4), hypertensive episodes (n=2), abdominal discomfort (n=2), 269 
asymptomatic self-limited hypotension and bradycardia (n=2), nausea (n=1), mild hematuria (n=1), 270 
hemothorax (n=1), severe pain requiring analgesics (n=1). ). All three hypertensive events were 271 
described in patients with pheochromocytomas (two of which were apparently non-secreting). Only 272 
one study reported a delayed  onset complication (needle track metastasis seeding (n=1))16. None of 273 
the four studies using  endoscopic ultrasound (EUS)  and providing information on complications, 274 
recorded any complications (Table 2). No relationship of the complication rate to the number of 275 
adrenal biopsies performed in a year was observed (R2= 0.0055). 276 
Diagnostic Accuracy Analysis  277 
An appropriate  reference standard was reported for 1096 adrenal masses and  included  pathology 278 
after adrenalectomy or autopsy  in 308 (28%) and either imaging or clinical follow up of 1 to 60 279 
months (when reported), Table 1. The diagnostic performance of adrenal biopsy was calculated 280 
using the data from the 8 studies (240 adrenal biopsy procedures) meeting pre-established eligibility 281 
criteria. Diagnostic performance was calculated separately for adrenocortical carcinoma  and 282 
metastases of an extra-adrenal primary tumor when disaggregation of patient data  was possible. 283 
The accuracy was assessed for diagnosing adrenocortical carcinoma (4 studies, n=107), metastasis 284 
of an extra-adrenal primary tumor (5 studies, n=131) and for overall malignancy (7 studies, n=217). 285 
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The sensitivity of adrenal biopsy for diagnosing any malignancy was 87% (78%-93%) and specificity  286 
was 100% (76%-100%). For diagnosing adrenocortical carcinoma, the  sensitivity was 70% (42%-287 
88%) and specificity 98% (86%-100%). For diagnosing metastasis of an extra-adrenal primary 288 
malignancy, sensitivity was 87% (74%-94%) and specificity 96%. Additional diagnostic accuracy 289 
measures (likelihood ratios and diagnostic odds ratios are given  in Table 4. 290 
Methodological quality 291 
Methodological quality was assessed by the QUADAS-2 tool in the 8 studies included in diagnostic 292 
accuracy meta-analysis (Supplemental figure 2). Limitations of the studies were not including 293 
consecutive or random patient population for biopsy studies and inappropriate exclusion of patients. 294 
These limitations increased the likelihood of bias in patient selection. The risk of bias for index test 295 
was low and risk of bias for reference standard was low to unclear for most of the included studies.  296 
The concerns for applicability in index test and the reference standard were low in majority of the 297 
studies.  298 
The quality of studies assessed by the Newcastle Ottawa quality assessment tool for studies 299 
reporting complications suggested the studies to be at a moderate risk for bias, most limitations 300 
related to patient selection, assessment of outcome and adequacy of follow up of the study 301 
population. 302 
 303 
Discussion: 304 
We present a systematic review of published experience with adrenal biopsy. Notably, while 32 305 
studies report at least one outcome of adrenal biopsy, mainly due to suboptimal reference 306 
standard we were only able to use data from 8 studies (240 biopsies) to calculate the diagnostic 307 
accuracy parameters for adrenal biopsy.  308 
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Based on these limited numbers we estimated that adrenal biopsy has 87% sensitivity and 100% 309 
specificity for the overall diagnosis of malignancy. Similar performance was noted for the diagnosis 310 
of metastases (sensitivity 87%, specificity 96%). Lower performance of adrenal biopsy in diagnosing 311 
adrenocortical carcinoma (sensitivity 70%, specificity 96%) could be explained by the well-known 312 
difficulties and challenges in differentiating between adrenocortical adenoma and carcinoma even 313 
when the entire tumor specimen is available. In addition, in the case of a biopsy it is more likely that 314 
tissue material is insufficient to apply all criteria for applying the Weiss score system that is usually 315 
used for discriminating benign from malignant adrenocortical masses.  All estimates are based on 316 
data derived from a fairly small sample size and 95% confidence intervals are wide. In addition, high 317 
risk of bias was observed especially in the patient selection domain of quality assessment raising 318 
concerns with applicability of these findings. Moreover, it is important to note that all diagnostic 319 
performance estimates are based only on “diagnostic” adrenal biopsies (where sufficient amount of 320 
cells was obtained). 321 
The rate of non-diagnostic biopsy varied significantly between studies from 0% to 28%with quite a 322 
high pooled rate of 8.7%. In the majority of cases a repeat adrenal biopsy was not performed. It is 323 
likely that the experience of the radiologists, adrenal biopsy technique and type of tumor biopsied 324 
influenced the likelihood of non-diagnostic biopsy (although we could not prove this in our 325 
analysis). However, it is obvious that additional factors (such as lack of applying the Weiss score 326 
upon pathological assessment) are also important, as illustrated in the ex-vivo study by Saeger et 327 
al where 10% of biopsies were non-diagnostic44. 328 
The pooled rate of complications was relatively low at 2.5%. However, most studies failed to 329 
describe in detail the information on how complications were collected and assessed. It is also likely 330 
that the retrospective nature of included studies contributed to the low pooled rate of complications. 331 
Adrenal biopsy is an invasive procedure and in some studies the rate of adverse events such as 332 
pneumothorax, pain and adrenal hemorrhage was as high as 13.6%13, 39. We have not found a 333 
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correlation between the adrenal biopsy volume/year (as a surrogate marker for radiologist’s 334 
experience) and the number of complications. In addition, adrenal biopsy technique could play a 335 
role, though we could not perform this analysis based on the data provided. Of note, in 4 out of 5 336 
studies done by the EUS-FNA technique, there were no complications related to the procedure. 337 
However, again the sample size was limited with a total of 300 biopsies. 338 
Inadvertent biopsy of pheochromocytomas can release catecholamines that may lead to severe 339 
adverse events20.  A significant number of patients presenting with chromaffin tumors were reported 340 
in our review. Most lacked biochemically screening for exclusion of pheochromocytoma prior to the 341 
adrenal biopsy resulting in several clinically significant hypertensive episodes. Endocrine evaluation 342 
prior to the adrenal biopsy (or at least biochemical  screening with metanephrines) should be 343 
instituted as standard of care as the adrenal biopsy procedure in a patient with pheochromocytoma 344 
is both unnecessary and dangerous.  345 
Strengths and limitations 346 
This is the first systematic review addressing the performance of adrenal biopsy. The strengths of 347 
this systematic review include an in-depth comprehensive literature search, a focused review 348 
question, duplicate review, pre-planned analysis and stringent inclusion criteria in terms of reference 349 
standard for diagnostic accuracy analysis to reduce bias.  350 
We acknowledge that our review has several limitations. The study population and adrenal biopsy 351 
procedure described in the studies included in our review were heterogeneous, which lowers our 352 
certainty in meta-analytic estimates. Another significant limitation was that most of the studies did 353 
not have optimal reference standard. The histological diagnoses included in the “benign adrenal 354 
biopsy” category varied in between studies. We limited this bias by excluding studies with more 355 
than 30% of lesions that could not be classified as benign (such as pheochromocytomas) in the 356 
benign cohort. 357 
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Definition and reporting of complication rates and non–diagnostic rates was inconsistent among the 358 
studies. We were not able to perform the subgroup analyses as we had planned related to needle 359 
gauge, number of passes and imaging technique used to perform biopsies due to heterogeneity and 360 
insufficient information available.   361 
It is important to note that most of the included studies were performed in large medical centers and 362 
could potentially overestimate performance of adrenal biopsy, however authors’ opinion is that such 363 
a procedure should indeed be limited to highly specialized adrenal centers.  364 
Conclusion 365 
Adrenal biopsy should be sparingly applied as it is an invasive procedure with variable diagnostic 366 
performance, an appreciable non-diagnostic and complication rate. Adrenal biopsy appears to be 367 
most useful for the diagnosis of adrenal metastasis in patients with a  newly detected adrenal mass 368 
and a history of extra-adrenal malignancy. The recommendation of the recent European Society of 369 
Endocrinology Guideline Panel on the management of adrenal incidentalomas is that an adrenal 370 
biopsy should only be performed if the expected findings are likely to alter the management of the 371 
individual patient and after biochemical exclusion of catecholamine-producing tumors to help prevent 372 
potentially life-threatening complications20. Prospective multi-center studies with detailed recording of 373 
adrenal biopsy procedures and outcomes following a pre-agreed diagnostic algorithm would be 374 
highly valuable to more accurately determine the diagnostic performance and factors determining the 375 
rates of non-diagnostic biopsies and complications associated with the procedure. 376 
 377 
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Table 1: Characteristics of included studies reporting on adrenal biopsy experience  
Author, 
year 
Cou
ntry 
Type of 
study* 
Time 
interval 
Population 
(details) 
Patie
nts 
(N) 
Aged 
y/o 
Wome
n 
(n/N) 
Malignant Benign 
 
Other Referenc
e 
standard 
Tikkako
ski, 
1991
 
Finla
nd 
RCS 1985 -
1990 
Mainly 
patients 
with 
known 
malignancy 
(70%) 
56 54.3 
(22-87 
) 
28/56 22 metastases 
1ACC 
1 lymphoma 
20 
adenomas 
3 hematoma 
1 pheochromocytoma 
1 lymph node 
5 adrenal cysts 
Adrenalectomy (n=13) 
Autopsy (n=2) 
Imaging follow up at 2 
months-5 years (n=39) 
Kane, 
1991 
USA RCS 1984 -
1989 
Patients 
with left 
adrenal 
mass 
47 Not 
reporte
d 
Not 
reporte
d 
Not reported Not reported 
Gillmas 
1992 
UK RCS 1985 - 
1990 
Patients 
with lung 
cancer 
16 66 (51-
74) 
Unclea
r 
5 metastases 8 “benign” 0 Death or imaging 
follow up 21-29 
months (n=7) 
No follow up (n=6) 
Silverm
an, 1993 
USA RCS Period 
not 
reported 
(9 
years) 
Mainly 
patients 
with 
known 
malignancy 
(68%) 
97 Not 
reporte
d 
Not 
reporte
d 
36 metastases 
2 lymphomas 
1 multiple 
myeloma 
3 
“malignant” 
41 “benign” 0 Adrenalectomy (n=8) 
Imaging follow up 
mean 16 months 
(n=16) 
Clinical follow up 
(n=8) 
Not reported (n=51) 
Dusenbe
ry, 1994 
USA RCS 1985-
1994 
All-comers 53 61 (34-
79) 
25/53 3 ACCs 
18 metastases 
1 lymphoma 
12 
adenomas 
 
1 “splenosis” 
1 myelolipoma 
Adrenalectomy (n=6) 
Clinical follow up 1-
60 months (n=22) 
No follow up (n=6) 
Saboori
an, 1994 
USA RCS 1986 -
1992 
Patients 
with 
known 
malignancy 
188 24-84 68/188 9 ACCs 
77 metastases 
3 lymphomas 
63 
adenomas 
5  
pheochromocytomas 
2 myelolipomas 
2 histoplasmosis 
granulomas 
Adrenalectomy (n=7) 
Not reported (n=154) 
Welch, 
1994 
USA RCS 1982 - 
1991 
Mainly 
patients 
with 
270 31-84 102/27
0 
78  
metastases# 
59 
“benign”# 
0 Clinical follow up of 
at least 1 year 
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known 
malignancy 
Burt, 
1994 
USA PCS Not 
reported 
Patients 
with lung 
cancer 
20 Not 
reporte
d 
Not 
reporte
d 
4 metastases 6 adenomas 0 Not reported 
Mody, 
1995 
USA RCS 1985 - 
1993 
Mainly 
patients 
with 
known 
malignancy 
(78%) 
78 61 (28-
88) 
32/78 31 
“malignant” 
47 “benign” 0 Not reported 
Hussain, 
1996 
USA RCS 1990 - 
1994 
All-comers 23 63 17/23 Not reported Not reported 
Wu, 
1998 
USA RCS 1990 - 
1996 
All-comers 162 Not 
reporte
d 
Not 
reporte
d 
6 ACCs 
73 metastases 
1 lymphoma 
9”malignant” 
50 
adenomas 
2 pheochromocytomas 
2 histoplasmosis 
granulomas 
1 adrenal cyst 
1 abscess 
Not reported 
Schwart
z, 1998 
USA RCS 1993 - 
1996 
Patients 
with lung 
cancer 
42 67 (41-
83) 
17/42 18 metastases 24 
adenomas 
0 Not reported 
Porte, 
1999 
Franc
e 
RCS 1991 - 
1997 
Patients 
with lung 
cancer 
32 43-74 2/32 18 metastases 14 
adenomas 
0 Adrenalectomy (n=9) 
Imaging follow up 6 
months (n=23) 
De 
Agustin, 
1999 
Spain RCS 1988 - 
1997 
All-comers 169 59 (1.2 
-76) 
24/169 55 
metastases, 1 
lymphoma + 
unclear 
number of 
ACCs as a 
part of “22 
primary 
adrenal 
tumor” group 
34 
“negative” + 
unclear 
number of 
other as a 
part of “22 
primary 
adrenal 
tumor” 
group 
5 neuroblastoma 
1 pheochromocytoma 
+ unclear number of 
other nonadenomas as 
a part of “22 primary 
adrenal tumor” group 
Adrenalectomy (n=16) 
Clinical follow up 
unclear length (n=153) 
Lumach
i, 2001 
Italy Unclear Not 
reported 
No history 
of 
malignancy
: 
73 49 (17-
80) 
44/73 10 ACCs 
4 metastases 
49 
adenomas 
7 pheochromocytomas Adrenalectomy (n=68) 
Imaging  follow up 
(n=2) 
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functioning 
and 
nonfunctio
ning 
adrenal 
masses 
Lumach
i, 2003 
Italy PCS 1999 - 
2001 
Patients 
with 
incidentalo
ma  >2 cm 
34 47 (26-
80) 
28/34 4 ACCs 
2 metastases 
24 
adenomas 
3 ganglioneuromas 
1 pheochromocytoma 
Adrenalectomy (n=19) 
Imaging follow up 12 
months (n=15) 
Paulsen, 
2003 
USA RCS 1998 - 
2002 
Patients 
with 
known or 
suspected 
malignancy 
50 26-86 20/50 4 ACCs 
32 metastases 
1 sarcoma, 1 
lymphoma, 1 
extraadrenal 
leiosarcoma 
6 adenomas 3 pheochromocytomas Adrenalectomy (n=1) 
Imaging follow up 23 
months (n=3) 
Not reported (n=56) 
Kocijan
čič30, 
2004 
Slove
nia 
RCS 1991 - 
2001 
Patients 
with lung 
cancer 
64 59 (42-
82) 
18/64 52 metastases 6 adenomas 0 Not reported 
Lucchi, 
2005 
Italy RCS 1993 - 
2003 
Patients 
with lung 
cancer 
13 65.7 
(50-78) 
1/13 10 metastases 3 adenomas 0 Adrenalectomy 
Lumach
i, 2007 
Italy PCS 2001 - 
2003 
Patients 
with 
unilateral 
incidentalo
ma  >3 cm 
42 54 
(25-75) 
24/42 8 ACCs 
4 metastases 
26 
adenomas 
2 ganglioneuromas 
2 pheochromocytomas 
Adrenalectomy 
Quayle, 
2007 
USA RCS 1997 - 
2006 
All-comers 22 60 
(31-80) 
10/22 3 ACCs 
3 metastases 
7 adenomas 4 pheochromocytomas 
1 paraganglioma 
1 hemorrhagic cyst 
1 hematoma 
2 myelolipomas 
Adrenalectomy (n=21) 
Imaging 
characteristics (n=3) 
Tsitouri
dis, 
2008 
Gree
ce 
RCS 2000 - 
2005 
All-comers 
with  
indetermin
ate adrenal 
masses 
(56% with 
57 58.8 
(33-82) 
27/57 3 ACCs 
29 metastases 
2 lymphoma 
20 
adenomas 
1 pheochromocytoma Adrenalectomy (n=4) 
Imaging follow up 6-
12 months (n=20) 
Not reported (n=31) 
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history of 
malignancy
) 
Osman, 
2009 
Egyp
t 
RCS 1992 - 
2005 
All-comers 
with  
indetermin
ate adrenal 
masses 
15 33.3 
(7-65) 
7/15 5 ACCs 
1 metastasis 
0 1 cystic teratoma 
5 pheochromocytomas 
1 schwannoma 
Adrenalectomy 
Mazzagl
ia, 2009 
USA RCS 1997 - 
2007 
All-comers 154 66 
(12.5) 
59/154 unclear unclear 0 Not reported 
Bodtger, 
2009 
Den
mark 
RCS 2000 - 
2006 
Patients 
with lung 
cancer and 
a left 
adrenal 
mass 
40 63 
(38-79) 
20/40 10 metastases 
1 
myosarcoma 
28 
adenomas 
1 teratoma Clinical follow up for 
21-86 months 
Eloubei
di, 2010 
USA Unclear 2000 - 
2007 
Patients 
with 
known 
malignancy 
59 63.8 
(47-49) 
22/59 22 metastases 37 “benign” 0 Presence of or 
suspected primary  
malignancy at another 
site and/ or imaging 
and /or clinical follow 
up 
Schuurb
iers, 
2011 
Neth
erlan
ds 
RCS 2001 - 
2009 
Patients 
with lung 
cancer and 
an FDG-
PET 
positive  
left adrenal 
mass 
85 65 
(37-86) 
34/85 1 ACC 
54 metastases 
25 
adenomas 
0 Clinical and 
radiological follow up 
for benign only 
Tyng, 
2012 
Brazi
l 
RCS 2009 - 
2010 
All-comers 13 64 
(48-84) 
2/13 9 metastases 4 adenomas 0 Follow up imaging at 
6 months (n=4) 
Tirabass
i, 2012 
Italy RCS 1990 - 
2010 
All-comers 
who 
subsequentl
y 
underwent 
adrenalecto
50 53.4 29/50 9 ACCs 
15 metastases 
19 
adenomas 
2 pheochromocytomas 
5 myelolipomas 
Adrenalectomy 
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my 
Rana, 
2012 
India RCS 2002 - 
2009 
All-comers 35 48.9 
(17-83) 
10/35 1 ACC 
7 metastases 
5 lymphomas 
0 2 neuroblastoma 
1 pheochromocytoma 
1 angiomyolipoma 
1 myelolipoma 
9 histoplasmosis 
granulomas 
4 tuberculosis 
granulomas 
Adrenalectomy (n=10) 
Clinical follow up (n= 
25) 
Martine
z, 2014 
USA RCS 1997 - 
2011 
All-comers 
(42% with 
history of 
malignancy
) 
 
94 66 (32-
86) 
45/94 1 ACC 
24 metastases 
58 
adenomas 
1 pheochromocytoma 
1 paraganglioma 
Clinical follow of  
unclear length (n=24), 
Adrenalectomy (n=6) 
Imaging follow up of 
at least 6 months 
(n=28) 
Other (n=3) 
No follow up (n=36) 
Puri, 
2015 
India PCS 2010 - 
2013 
All-comers 21 56 
(12.2) 
7/21 7 metastases 0 1 myelolipoma 
1 lipoma 
10 tuberculosis 
granulomas 
2 histoplasmosis 
granulomas 
Unclear: imaging 
characteristics, clinical 
follow up for 3 years 
*Retrospective cohort study: RCS, Prospective cohort study: PCS, #Reported for lung cancer patients only
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Table 2: Description of the adrenal biopsy procedure, non-diagnostic rates and complications 
Author, year Biopsi
es (N) 
Adrenal biopsy 
procedure 
 
Needle 
gauge 
Number 
of passes 
Adrenal mass 
diameter (cm) 
Nondiagnostic 
rate n1/N 
Complicatio
n rate n2/N 
Complications in details 
Tikkakoski, 
1991
 
56 CT-guided (11) 
US - guided (45) 
(fine needle 
biopsy) 
Not 
reported 
Not 
reported 
Not reported 2/56 0/56  
Kane, 1991 33 CT-guided, 
anterior approach, 
left adrenal only 
(tandem needle 
technique) 
20-22 1-6 Not reported 1/33 2/33 Pancreatitis leading to 11-13 days 
hospitalization (n=2) 
Gillmas 1992 16 CT-guided 
(FNA) 
18,20 3 2.6 (1.1 - 8) 3/16 1/16 Small pneumothorax (n=1) 
Silverman, 
1993 
101 CT-guided (86) 
US-guided (15) 
(unclear 
technique) 
19-22 Not 
reported 
Not reported 18/101 9/101 Mild abdominal discomfort (n=2) 
Nausea (n=1) 
Mild hematuria (n=1) 
Asymptomatic self-limited 
hypotension and bradycardia (n= 
2) 
Pneumothorax (n=2), one patient 
requiring tube placement 
Hemothorax, requiring chest 
drainage (n=1) 
Dusenbery, 
1994 
54 Not reported 
((FNA in 43, core 
in 11) 
Not 
reported 
Not 
reported 
Not reported 18/54 Not reported  
Saboorian, 
1994 
188 Not reported 
(FNA) 
18-22 Not 
reported 
Benign: 
2.4(0.8) 
 ACC: 10.6(6) 
Metastases: 
5(2.5) 
27/188 Not reported  
Welch, 1994 277 CT-guided (271) 
US - guided (6) 
(unclear 
technique) 
16-23 
 
Not 
reported 
3.8 (1-12) 10/147 
(provided only 
for lung cancer 
patients) 
8/277 
 
Only major complications reported 
(requiring hospitalization or 
intervention): 
Perirenal hematoma (n=1) 
Adrenal hematomas (n=7) 
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Burt, 1994 20 CT-guided 
(needle aspiration) 
Not 
reported 
Not 
reported 
2.2 (1.2-7.1) 10/20 Not reported  
Mody, 1995 83 CT-guided (79) 
US-guided (4) 
(FNA for all + 
biopsy gun for 2) 
18-22 1-7 3.5 5/83 7/83 Pneumothorax requiring tube 
placement (n=1) 
Self-resolved pneumothorax (n=1) 
Perinephric hematoma (n=2) 
Intra-hepatic hematoma (n=1) 
Subcapsular hematoma (n=1) 
Needle-track metastasis seeding 
(n=1) 
Hussain, 1996 26 CT-guided 
(angle gantry 
technique) 
18-22 3 1.25 (0.6-4) 6/26 0/26  
Wu, 1998 162 Not reported 
FNA 
20-23 3 Not reported 17/162 Not reported  
Schwartz, 1998 42 CT-guided 
(?core) 
22 Not 
reported 
Benign: 1.9 (1-
4) 
Malignant 4.3 
(1-7.6) 
0/42 3/42 Pneumothorax not requiring 
hospitalization (n=3) 
Porte, 1999 32 CT-guided 
(?core) 
19,22 Not 
reported 
Not reported 0/32 0/32  
De Agustin, 
1999 
169 CT-guided 
FNA 
22 Not 
reported 
Not reported 47/169 unclear “no serious complications 
observed” 
Lumachi, 2001 73 CT-guided (52), 
US-guided (18) 
FNA 
21-23  4.23 (1.71) 3/73 3/73 Self-resolved pneumothorax (n=2) 
Hematoma (n=1) 
 
Lumachi, 2003 34 CT-guided (14) 
US-guided (20) 
FNA 
21-23 Not 
reported 
Benign: 
4.3(1.4) 
Malignant: 
6.3(2.2) 
Not reported 1/34 Self-resolved pneumothorax (n=1) 
 
Paulsen, 2003 50 CT-guided (41) 
US-guided (9) 
FNA (3) and core 
(47) 
16-22 3 4.9 (1.5–16) 2/50 0/50  
Kocijančič30, 
2004 
64 US-guided FNA 22 Not 
reported 
5.6 (2.5-13) 6/64 4/64 Self-resolved pain (n=4) 
Lucchi, 2005 13 CT and US-guided 
FNA 
Not 
reported 
Not 
reported 
4.6 (2-10) Not reported 0/13  
Page 28 of 37
3 
 
Lumachi, 2007 42 CT-guided (11) 
US-guided (31) 
FNA 
23 Not 
reported, 
cit 4 
6.9 (5.1) 2/42 2/42 Self-resolved pneumothorax (n=1) 
Severe pain requiring analgesic 
therapy (n = 1) 
Quayle, 2007 22 Not reported 
(needle biopsy) 
Not 
reported 
Not 
reported 
5.1 (3-10) 6/22 3/22 Hepatic hematoma (n=1) 
Hemothorax (n=1) 
Duodenal hematoma requiring 
hospitalization (n=1) 
Tsitouridis, 
2008 
57 CT-guided 
(technique varied) 
16- 22 Not 
reported 
3.9 (1.3 -7.8) 
 
2/57 3/57 Self-resolved hematoma  (n=2) 
Self-resolved pneumothorax (n=1) 
Osman, 2009 15 CT-guided (12) 
US-guied (3) 
(biopsy gun 
technique) 
18  7.7 (1-15) 2/15 2/15 
Hypertensive episode (n=2) 
Mazzaglia, 
2009 
163 Not reported Not 
reported 
Not 
reported 
3.9 (2.2) 2/163 unclear "few" complications including one 
described  hematoma and pain 
Bodtger, 2009 40 Endoscopic US-
guided FNA, left 
adrenal only 
22 1-3 2 (0.6-6) 
 
2/40 0/40  
Eloubeidi, 
2010 
59 Endoscopic US-
guided FNA 
22 3 (1-4) Benign: 2.3 
Malignant: 3.1 
0/59 0/59  
Schuurbiers, 
2011 
85 Endoscopic US-
guided FNA, left 
adrenal only 
22 3 (1-6) 2.86 (1.91) 5/85 0/85  
Tyng, 2012 13 CT-guided, 
paravertebral 
hydrodissection 
technique 
17, 18 Not 
reported 
4.1 (1.3-8.4) 0/13 0/13  
Tirabassi, 2012 50 US-guided FNA 22  Benign: 5.4 
ACC: 4.6 
Metastases: 5 
11/50 2/50 Pneumothroax (n=1) 
Hypertensive crisis (n=1) 
Rana, 2012 35 CT and US-guided 
FNA 
18-22  Not reported 4/35 0/35  
Martinez, 2014 95 Endoscopic US-
guided FNA 
19, 22 or 
25 
mean 3.2 
± 1.4 
Right: 3.5 
(0.88) 
Left: 2.72 
(1.36) 
9/95 Not reported  
Puri, 2015 21 Endoscopic US-
guided FNA 
22 median 
4(range 3-
7) 
2.4 0/21 0/21  
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*FNA – fine needle aspiration 
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Table 3: Origin of Adrenal Metastases reported in included studies*  
 
Author, year 
Metastases 
(n) 
Lung 
Gastro-
intestinal 
Kidney Melanoma Breast Prostate Bladder 
Other + 
unknown 
primary 
Tikkakoski, 
1991
 22 15 2 3 1 
   
1 
Dusenbery, 
1994 18 8 4 1 1 
  
1 3 
Saboorian, 1994 
77 55 4 7 5 1 
 
1 4 
Wu, 1998 
82 40 9 14 2 1 
 
1 15 
De Agustin, 
1999 55 26 4 1 2 1 1 1 19 
Lumachi, 2001 
4 4 
       
Lumachi, 2003 
2 2 
       
Paulsen, 2003 
32 22 4 2 1 
   
3 
Quayle, 2007 
3 
  
2 1 
    
Tsitouridis, 
2008 29 18 3 2 1 4 
  
1 
Osman, 2009 
1 
      
1 
 
Eloubeidi, 2010 
22 17 1 
 
2 
  
1 1 
Tyng, 2012 
9 2 1 3 
    
3 
Tirabassi, 2012 
15 7 
 
3 1 3 
  
1 
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Rana, 2012 
7 2 1 2 
  
1 1 
 
Martinez, 2014 
24 10 9 2 1 1 
  
1 
Puri, 2015 
7 6 1 
      
TOTAL 409 234 43 42 18 11 2 7 52 
*studies performed exclusively on lung cancer patients were excluded 
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Table 4: Diagnostic performance of adrenal biopsy 
 Diagnosis of malignancy# 
(7 studies, 217 patients) 
Diagnosis of ACC* 
(4 studies, 107 patients) 
Diagnosis of metastasis 
(5 studies, 131 patients) 
 Estimate 95% CI Estimate 95% CI Estimate 95% CI 
Sensitivity 87% 78% 93% 70% 42% 88% 87% 74% 94% 
Specificity 100% 76% 100% 98% 86% 100% 96% 89% 98% 
LR+ 229.4 2.9 18145.3 100.43 8.10 1245.43 19.8 7.4 53.1 
LR- 0.13 0.07 0.23 30.86 4.16 228.80 0.13 0.06 0.28 
DOR 1775 22 142702 0.31 0.14 0.70 151 41 560 
 
#includes metastases, adrenal cortical carcinoma and other adrenal malignancies (lymphoma, sarcoma, etc) 
*ACC: Adrenocortical Carcinoma 
DOR: Diagnostic odds ratio 
LR: likelihood ratio 
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Figure 1: Non-diagnostic adrenal biopsies* 
 
 
*defined as failure to obtain sufficient amount of cytology material to make a diagnosis 
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Figure 2: Adrenal biopsy related complications 
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Supplemental Figure 1: Prisma Flow diagram 
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Supplemental Figure 2: QUADAS2 for 8 studies included in the diagnostic accuracy analysis 
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